RU2011127333A - Лечение боли - Google Patents
Лечение боли Download PDFInfo
- Publication number
- RU2011127333A RU2011127333A RU2011127333/15A RU2011127333A RU2011127333A RU 2011127333 A RU2011127333 A RU 2011127333A RU 2011127333/15 A RU2011127333/15 A RU 2011127333/15A RU 2011127333 A RU2011127333 A RU 2011127333A RU 2011127333 A RU2011127333 A RU 2011127333A
- Authority
- RU
- Russia
- Prior art keywords
- pain
- antagonist
- subject
- specified
- csf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
1. Способ лечения боли у субъекта, включающий введение субъекту антагониста гранулоцитарно-макрофагального колониестимулирующего фактора (GM-CSF).2. Способ по п.1, где указанный субъект представляет собой человека.3. Способ по п.1, где указанный антагонист представляет собой антитело, специфичное в отношении GM-CSF.4. Способ по п.1, где указанный антагонист представляет собой антитело, специфичное в отношении рецептора GM-CSF.5. Способ по п.1, где указанная боль представляет собой послеоперационную боль.6. Способ по п.1, где указанная боль представляет собой боль, обусловленную раком кости.7. Способ по п.1, где указанная боль представляет собой боль, обусловленную ревматоидным артритом.8. Способ по п.1, где указанная боль представляет собой боль, обусловленную остеоартритом.9. Способ по п.1, где указанная боль представляет собой воспалительную боль.
Claims (9)
1. Способ лечения боли у субъекта, включающий введение субъекту антагониста гранулоцитарно-макрофагального колониестимулирующего фактора (GM-CSF).
2. Способ по п.1, где указанный субъект представляет собой человека.
3. Способ по п.1, где указанный антагонист представляет собой антитело, специфичное в отношении GM-CSF.
4. Способ по п.1, где указанный антагонист представляет собой антитело, специфичное в отношении рецептора GM-CSF.
5. Способ по п.1, где указанная боль представляет собой послеоперационную боль.
6. Способ по п.1, где указанная боль представляет собой боль, обусловленную раком кости.
7. Способ по п.1, где указанная боль представляет собой боль, обусловленную ревматоидным артритом.
8. Способ по п.1, где указанная боль представляет собой боль, обусловленную остеоартритом.
9. Способ по п.1, где указанная боль представляет собой воспалительную боль.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13968708P | 2008-12-22 | 2008-12-22 | |
| US61/139,687 | 2008-12-22 | ||
| US16449109P | 2009-03-30 | 2009-03-30 | |
| US61/164,491 | 2009-03-30 | ||
| PCT/AU2009/001671 WO2010071923A1 (en) | 2008-12-22 | 2009-12-21 | Pain treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016102346A Division RU2712166C2 (ru) | 2008-12-22 | 2009-12-21 | Лечение боли |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2011127333A true RU2011127333A (ru) | 2013-01-27 |
| RU2630969C2 RU2630969C2 (ru) | 2017-09-15 |
Family
ID=42286785
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011127333A RU2630969C2 (ru) | 2008-12-22 | 2009-12-21 | Лечение боли |
| RU2016102346A RU2712166C2 (ru) | 2008-12-22 | 2009-12-21 | Лечение боли |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016102346A RU2712166C2 (ru) | 2008-12-22 | 2009-12-21 | Лечение боли |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8475796B2 (ru) |
| EP (2) | EP2387418B1 (ru) |
| JP (3) | JP5674677B2 (ru) |
| KR (1) | KR101761324B1 (ru) |
| CN (2) | CN108014335A (ru) |
| AU (2) | AU2009329811B2 (ru) |
| BR (1) | BRPI0918103A2 (ru) |
| CA (1) | CA2747206C (ru) |
| ES (1) | ES2685895T3 (ru) |
| HK (2) | HK1255046A1 (ru) |
| RU (2) | RU2630969C2 (ru) |
| WO (1) | WO2010071923A1 (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3056217B1 (en) | 2008-12-22 | 2021-06-30 | The University of Melbourne | Osteoarthritis treatment |
| KR101761324B1 (ko) | 2008-12-22 | 2017-07-25 | 더 유니버시티 오브 멜버른 | 통증 치료 |
| KR20230041086A (ko) | 2012-09-20 | 2023-03-23 | 모르포시스 아게 | 류마티스 관절염에 대한 치료 |
| KR20210021153A (ko) * | 2012-09-20 | 2021-02-24 | 모르포시스 아게 | 류마티스 관절염에 대한 치료 |
| AR093297A1 (es) | 2012-10-31 | 2015-05-27 | Amgen Res (Munich) Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| US9833410B2 (en) | 2012-10-31 | 2017-12-05 | Takeda Gmbh | Lyophilized formulation comprising GM-CSF neutralizing compound |
| US20160024200A1 (en) * | 2013-03-14 | 2016-01-28 | John Schrader | Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof |
| BR112016003293A8 (pt) | 2013-08-30 | 2022-08-16 | Takeda Gmbh | Anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos |
| CN107840885B (zh) * | 2016-09-19 | 2020-11-10 | 天境生物科技(上海)有限公司 | Gm-csf抗体及其用途 |
| CA3036509C (en) * | 2016-09-19 | 2022-10-25 | I-Mab | Anti-gm-csf antibodies and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT63181A (en) * | 1989-07-14 | 1993-07-28 | Schering Corp | Process for producing gm-csf antagonists originating from carboxy terminal of gm-csf |
| DK0486572T3 (da) | 1989-08-11 | 1998-05-04 | Amrad Corp Ltd | Forbedringer i granulocyt-makrofag-kolonistimulerende faktorreceptor og derivater deraf |
| US5747032A (en) | 1990-08-10 | 1998-05-05 | Amrad Corporation Limited | Monoclonal antibody to human granulocyte macrophage colony stimulating factor |
| WO1994011404A1 (en) * | 1992-11-19 | 1994-05-26 | Dana-Farber Cancer Institute | Antibodies for gm-csf receptor and uses thereof |
| ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| AUPP525198A0 (en) | 1998-08-13 | 1998-09-03 | Medvet Science Pty. Ltd. | Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof |
| US7108852B2 (en) | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| US7455836B2 (en) | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
| SE0102067D0 (sv) * | 2001-06-11 | 2001-06-11 | A & Science Invest Ab | Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation |
| WO2003035048A2 (en) | 2001-10-26 | 2003-05-01 | Novartis Ag | Methods for the treatment of osteoarthritis and compositions thereof |
| ATE509032T1 (de) | 2002-02-13 | 2011-05-15 | Ludwig Inst For Cancer Res Ltd | Chimerizierte gm-csf antikörper |
| AU2002950957A0 (en) * | 2002-08-23 | 2002-09-12 | The Walter And Eliza Hall Institute Of Medical Research | A method of treatment and prophylaxis |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| US20040241755A1 (en) | 2003-06-02 | 2004-12-02 | Pfizer Inc. | Human cell assay to determine effect of sample compounds on Col2 enhancer expression |
| EP1759710B1 (en) | 2004-03-31 | 2014-05-07 | Kazuwa Nakao | Remedy or preventive for arthritis |
| EP1593690B1 (en) | 2004-05-05 | 2009-07-01 | Micromet AG | Preparation of ScFv antibody fragments |
| SG161292A1 (en) | 2005-04-18 | 2010-05-27 | Micromet Ag | Antibody neutralizers of human granulocyte macrophage colony stimulating factor |
| DK1888643T3 (en) * | 2005-05-18 | 2015-01-05 | Morphosys Ag | Anti-GM-CSF antibodies as well as their uses |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| EP1957537A2 (en) | 2005-12-01 | 2008-08-20 | Domantis Limited | Competitive domain antibody formats that bind interleukin 1 receptor type 1 |
| CN101501070B (zh) | 2006-02-08 | 2013-12-25 | 诺福泰克公司 | 抗原性gm-csf肽和针对gm-csf的抗体 |
| PL2423230T3 (pl) | 2006-03-27 | 2013-10-31 | Medimmune Ltd | Element wiążący dla receptora GM-CSF |
| US7741273B2 (en) * | 2006-04-13 | 2010-06-22 | Warsaw Orthopedic, Inc. | Drug depot implant designs |
| AU2007323541B2 (en) | 2006-11-21 | 2012-01-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating chronic inflammatory diseases using a GM-CSF antagonist |
| WO2008080134A2 (en) | 2006-12-22 | 2008-07-03 | Rigel Pharmaceuticals, Inc. | 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors |
| AU2008253608A1 (en) | 2007-05-23 | 2008-11-27 | Crc For Asthma And Airways Ltd | Neutralizing antibodies |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| WO2009062238A1 (en) | 2007-11-12 | 2009-05-22 | Crc For Asthma And Airways Ltd | Epitope for neutralizing antibodies |
| NZ597023A (en) | 2007-11-13 | 2013-07-26 | Boehringer Ingelheim Int | Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same |
| NZ588850A (en) | 2008-04-28 | 2012-12-21 | Kalobios Pharmaceuticals Inc | Antibodies to granulocyte-macrophage colony-stimulating factor |
| EP3056217B1 (en) | 2008-12-22 | 2021-06-30 | The University of Melbourne | Osteoarthritis treatment |
| KR101761324B1 (ko) | 2008-12-22 | 2017-07-25 | 더 유니버시티 오브 멜버른 | 통증 치료 |
| US8609101B2 (en) | 2009-04-23 | 2013-12-17 | Theraclone Sciences, Inc. | Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies |
-
2009
- 2009-12-21 KR KR1020117017019A patent/KR101761324B1/ko active IP Right Grant
- 2009-12-21 CN CN201711112956.0A patent/CN108014335A/zh active Pending
- 2009-12-21 AU AU2009329811A patent/AU2009329811B2/en active Active
- 2009-12-21 EP EP09833923.7A patent/EP2387418B1/en active Active
- 2009-12-21 EP EP18170226.7A patent/EP3381471B1/en active Active
- 2009-12-21 CA CA2747206A patent/CA2747206C/en active Active
- 2009-12-21 RU RU2011127333A patent/RU2630969C2/ru active
- 2009-12-21 JP JP2011541029A patent/JP5674677B2/ja active Active
- 2009-12-21 CN CN200980151639.7A patent/CN102256621B/zh active Active
- 2009-12-21 US US13/140,839 patent/US8475796B2/en active Active
- 2009-12-21 RU RU2016102346A patent/RU2712166C2/ru active
- 2009-12-21 ES ES09833923.7T patent/ES2685895T3/es active Active
- 2009-12-21 WO PCT/AU2009/001671 patent/WO2010071923A1/en active Application Filing
- 2009-12-21 BR BRPI0918103A patent/BRPI0918103A2/pt not_active Application Discontinuation
-
2013
- 2013-05-28 US US13/903,009 patent/US9352034B2/en active Active
-
2014
- 2014-07-04 JP JP2014138170A patent/JP6147704B2/ja active Active
-
2016
- 2016-01-18 AU AU2016200267A patent/AU2016200267B2/en active Active
- 2016-04-29 US US15/142,746 patent/US9834599B2/en active Active
-
2017
- 2017-04-05 JP JP2017074868A patent/JP2017149740A/ja active Pending
-
2018
- 2018-11-07 HK HK18114170.3A patent/HK1255046A1/zh unknown
- 2018-11-09 HK HK18114356.9A patent/HK1255227A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011127333A (ru) | Лечение боли | |
| RU2011127334A (ru) | Лечение остеоартрита | |
| RU2012110882A (ru) | Производные 6-аминохиназолина или 3-цианохинолина, способы их получения и их фармацевтические применения | |
| EA201170922A1 (ru) | Производные сульфонамида | |
| EA201100880A1 (ru) | Бензонафтиридиновые соединения в качестве ингибиторов аутотаксина | |
| MX2019006655A (es) | Antagonistas de actriib y dosificacion y uso de los mismos. | |
| EA201290189A1 (ru) | Человеческие нейтрализующие антитела анти-ngf в качестве селективных ингибиторов метаболических путей фактора роста нервов | |
| EA201200260A1 (ru) | Гетероциклические гидразоны и их применение для лечения рака и воспаления | |
| EA201290254A1 (ru) | Антагонисты il-17a | |
| MY146986A (en) | Methods for treating interleukin-6 related diseases | |
| BRPI0510177A (pt) | heterociclos monocìclicos como inibidores de cinase | |
| EA201100030A1 (ru) | Пиразольные соединения 436 | |
| MX2007006355A (es) | Epitopes antigenos de interleucina-21, anticuerpos relacionados y su uso en el campo medico. | |
| BR112013033182A2 (pt) | compostos imidazopiridinil-aminopiridina substituída | |
| EA201200318A1 (ru) | Гетероциклические оксимы | |
| EA201000094A1 (ru) | Производные пиримидинил-пиридазинона | |
| RU2012103850A (ru) | Би-арил-мета-пиримидиновые ингибиторы киназ | |
| TW200738725A (en) | Unsaturated mTOR inhibitors | |
| IL219145A0 (en) | Use of an antagonist molecule for preparing a medicament for treating diseases which are mediated by cutaneous lymphocyte antigen positive cells | |
| EA201200938A1 (ru) | Производные имидазопиридина в качестве ингибиторов jak | |
| EA201400333A1 (ru) | Бензонитрильные производные в качестве ингибиторов киназ | |
| EA200901601A1 (ru) | Производные пиридазинона | |
| EA200901611A1 (ru) | Производные 2-оксо-3-бензил-бензоксазол-2-она и родственные соединения в качестве ингибиторов мет киназы для лечения опухолей | |
| MY147649A (en) | Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders | |
| JP2012512814A5 (ru) |